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AbstrAct
Purpose Globally, prostate cancer treatment and 
outcomes for men vary according to where they live, 
their race and the care they receive. The TrueNTH Global 
Registry project was established as an international 
registry monitoring care provided to men with localised 
prostate cancer (CaP).
Participants Sites with existing CaP databases 
in Movember fundraising countries were invited to 
participate in the international registry. In total, 25 Local 
Data Centres (LDCs) representing 113 participating 
sites across 13 countries have nominated to contribute 
to the project. It will collect a dataset based on the 
International Consortium for Health Outcome Measures 
(ICHOM) standardised dataset for localised CaP.
Findings to date A governance strategy has been 
developed to oversee registry operation, including 
transmission of reversibly anonymised data. LDCs are 
represented on the Project Steering Committee, reporting 
to an Executive Committee. A Project Coordination 
Centre and Data Coordination Centre (DCC) have been 
established. A project was undertaken to compare 
existing datasets, understand capacity at project 
commencement (baseline) to collect the ICHOM dataset 
and assist in determining the final data dictionary. 21/25 
LDCs provided data dictionaries for review. Some ICHOM 
data fields were well collected (diagnosis, treatment 
start dates) and others poorly collected (complications, 
comorbidities). 17/94 (18%) ICHOM data fields were 
relegated to non-mandatory fields due to poor capture by 
most existing registries. Participating sites will transmit 
data through a web interface biannually to the DCC.
Future plans Recruitment to the TrueNTH Global 
Registry-PCOR project will commence in late 2017 
with sites progressively contributing reversibly 
anonymised data following ethical review in local 
regions. Researchers will have capacity to source 
deidentified data after the establishment phase. Quality 
indicators are to be established through a modified 
Delphi approach in later 2017, and it is anticipated that 
reports on performance against quality indicators will be 
provided to LDCs.
IntroductIon
Globally, prostate cancer is the second most 
commonly diagnosed cancer, behind lung 
cancer, and, in the developed world, it is 
the most common cancer among men.1 
Survival has increased dramatically over the 
past 25 years. In developed countries, 92% 
of men are alive 5 years after diagnosis, with 
survival as high as 97% for men diagnosed 
before the age of 60.2 However, in low-in-
come, middle-income countries survival rates 
are approximately half that of developed 
countries; 5-year survival in Indonesia is 44% 
and in both Thailand and India is 58%.3 Vari-
ation in incidence and outcomes also exists 
between racial groups, with the rate ratio of 
black:white men for prostate cancer incidence 
and mortality being 1.7 and 2.4, respectively.4 
Variation in survival has principally been the 
result of lead time bias attributable to early 
diagnosis of asymptomatic disease. It has also, 
in some part, been due to variation in the 
quality of healthcare.5–7 
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Cohort profile
strengths and limitations of this study
 ► To our knowledge, this is the largest clinical quality 
registry (CQR) to have been developed; it involves 
collecting data from, and reporting health outcomes 
to, contributing health services across 13 countries.
 ► We outline the approach taken to establishing a 
CQR to monitor care provided to men with localised 
prostate cancer, including how the minimum dataset 
was determined, the governance structure and data 
security, hosting and access arrangements. It will 
assist researchers embarking on developing an 
international CQR.
 ► We were unable to report the capability for 4/21 
Local Data Centres to contribute the required data 
fields to the global registry because we did not 
translate data dictionaries to English.
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This makes understanding variation in management 
of prostate cancer very important. Measuring variation 
in prostate cancer care and outcomes has tradition-
ally been by assessment of compliance with evidence-
based guidelines using quality indicators.8–10 Comparing 
performance of quality indicators across sites or bench-
marking performance requires data fields to be consis-
tently defined and collected at the same time points. The 
International Consortium for Health Outcome Measures 
(ICHOM) has developed standardised datasets for local-
ised and advanced prostate cancer in an effort to improve 
the ability to compare health outcomes.11 12 These 
datasets provide a consistent approach to defining and 
recording data items and time points for their collection. 
The premise for development of standardised datasets by 
ICHOM was to encourage value-based healthcare13 and 
foster ‘positive deviance’ research,14 whereby all partici-
pating health services learn from those achieving excel-
lent outcomes. In effect, the goal was to raise the bar for 
quality.
The TrueNTH Global Registry  is an international 
registry to monitor prostate cancer care, applying the 
principles of collecting and using the ICHOM stan-
dardised clinical dataset. The TrueNTH Global Registry 
project aims to significantly improve the physical and 
mental health of men treated for prostate cancer by (i) 
examining the extent to which current practice in partici-
pating sites reflects evidence-based guidelines; (ii) system-
atically measuring clinical and patient-reported outcomes 
and key elements of care that have the potential to 
impact outcomes; (iii) comparing and sharing deidenti-
fied outcomes between participating sites; (iv) analysing 
variations to understand key drivers that deliver the best 
outcomes and (v) mobilising the exchange of knowledge 
among the prostate cancer clinicians, treating facilities 
and men diagnosed with prostate cancer.
The aim of this paper is to describe the methods used 
to develop the TrueNTH Global Registry project, an 
international registry for localised CaP. This paper is not 
a classical research paper but rather a cohort profile; it 
attempts to develop, in line with the respect of scientific 
approach, a working platform detailing how the registry 
will function. The approach outlined herein may assist 
other clinical specialties in developing an implementa-
tion model for an international clinical quality registry 
using a standardised clinical dataset, such as those devel-
oped by ICHOM.
cohort descrIPtIon
establishing the cohort and governance arrangements
In mid-2015, two parallel Expressions of Interest were 
extended to participate in the TrueNTH Global Registry 
project through authorised legal entities in countries 
where the Movember Foundation has a significant fund-
raising presence. The first was a call to nominate as the 
Global Project Coordination Centre and the second was 
to nominate as a participating site. Nominating sites 
were required to demonstrate some existing capacity 
to prospectively collect the ICHOM minimum dataset. 
Sites were advised that funding was available to assist 
in collecting data fields required by ICHOM but not 
currently being collected, and to support costs of trans-
ferring data to a central global coordination centre for 
analysis and development of benchmark reports. The 
Expression of Interest stipulated that initial funding 
would be provided for 3 years, after which an evaluation 
would be undertaken to assess future funding, based on 
the extent to which the TrueNTH Global Registry project 
achieved its intended projects aims.
A Project Coordination Centre (PCC) and Data Coor-
dination Centre (DCC) were appointed through a 
competitive peer-review process; the PCC based at the 
University of California, Los Angeles, and the DCC at 
Monash University in Australia. In total, 25 responses to 
the Expression of Interest were received from 12 coun-
tries. Together these respondents had capacity to collect 
data from 113 participating sites in 13 countries. Thirteen 
respondents nominated as single institutions, with the 
remaining respondents nominating to act on behalf of 
between 2 and 24 participating sites. Sites nominating to 
transmit data to the DCC were referred to as Local Data 
Centres (LDCs) figure 1 provides a summary of the LDCs 
and participating sites from each country nominating to 
be included in the TrueNTH Global Registry project.
A governance framework was developed by Movember in 
collaboration with their Global Prostate Cancer Outcomes 
Steering Committee (figure 2). The PCC is responsible 
for the establishment and delivery of a project commu-
nication plan, stewardship of meetings of the Executive 
Committee and Project Steering Committee, monitoring 
of regulatory approvals in participating sites, guidance 
and development of methodological approaches to the 
data analyses, evaluation and interpretation of statistical 
output, provision of descriptive analysis of variations 
in outcomes across participating sites; development of 
hypotheses to explain variations in quality and outcomes 
among participating sites and coordination of activity to 
identify strategies and actions to test these hypotheses.
The DCC will oversee data management and contribute 
to the projects’ execution with representation on the 
TrueNTH Global Registry Executive Committee. The role 
of the DCC includes developing the global register, its 
data dictionary and the TrueNTH Global Registryinitial 
protocol draft; building a technical solution for the secure 
transfer of data from sites to the DCC and training sites 
on its use; providing a research portal to enable partici-
pating sites to gain secure access to data (following rele-
vant ethical approval); and leading a process to develop 
quality indicators to report back to participating sites.
The LDC may represent numerous hospitals or insti-
tutions or may be individual sites collecting data directly 
from patients. LDCs will be responsible for transmitting 
data to, and distributing reports from, the DCC. A clin-
ical lead will be appointed for each LDC as the primary 
contact for the project.
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Figure 1 Details of the 12 countries nominating to participate in the TrueNTH Global Registry and distribution of the 113 
participating sites across the 25 Local Data Centres in these 12 countries.
Figure 2 Details of the governance hierarchy established for the TrueNTH Global Registry . At least one clinical lead from each 
country will contribute to the TrueNTH Global Registry Steering Committee.
A TrueNTH Global RegistryExecutive Committee 
was formed with clinician, epidemiologist and scientist 
representatives, and members of the DCC, the PCC and 
the Movember Foundation. Its responsibilities include 
reviewing and endorsing the project work plan, protocol, 
quality indicator set, standard operating procedures and 
terms of reference for committees and working groups; 
monitoring progress of participating sites and LDCs; and 
identifying opportunities for improvement in quality 
of care and reviewing suggestions made by the Project 
Steering Committee.
The Project Steering Committee includes representa-
tives from each contributing country (nominated from 
the clinical leads of the LDCs), the PCC, DCC, Movember 
Foundation, the Executive Committee and at least one 
consumer and quality-of-care expert. It will initially select 
the quality indicators and how they will be presented 
and will review prostate cancer management processes 
and structures across contributing sites to identify those 
factors associated with high-quality care. A Communica-
tion and Action Plan will be created with the Committee 
to maximise the exchange of knowledge and facilitate 
opportunities for policy transformation and funding for 
prostate cancer innovation projects.
FIndIngs to dAte
A Data Discovery study was initiated in late 2015 with sites 
responding to the Expression of Interest to assess existing 
capacity to collect the ICHOM standardised dataset 
and finalise the dataset to be collected by the TrueNTH 
Global Registry project. Nominating sites were asked to 
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Figure 3 Distribution of data items collected by the 21 Local Data Centres across the categories of (1) patient factors and 
quality-of-life, (2) baseline tumour factors, (3) treatment, (4) pathology information, (5) acute complications of treatment and   
(6) survival and disease control.
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Table 1 Summary of amendments to the existing International Consortium for Health Outcome Measures (ICHOM) dataset 
and new fields introduced into the TrueNTH Global Registry project
Amendments to the existing 
ICHOM data fields
Patient-reported quality of life to only be collected as a mandatory (Tier 1) field at baseline and 
12 months post diagnosis/treatment. Other time points will be non-mandatory (Tier 2)
Comorbidities will only be Tier 2 at baseline
Stop date for focal therapy will be removed as this is a day procedure
Androgen deprivation therapy (ADT) will be split into chemical and surgical groups
New mandatory (Tier 1) fields 
introduced
Clinical metastases stage
Surgical approach (open, robot-assisted, laparoscopic, conversion)
ADT chemical agents
Date of orchidectomy
Whole gland ablation and date of initiation
New non-mandatory (Tier 2) 
fields introduced
Method of diagnosis
Use of radiological tests (MRI, bone scans, CT and PET scans) to target biopsies and/or assist 
in staging at baseline and prior to primary treatment initiation (if different to baseline).
MRI, bone scans, CT and PET scan dates
Details of the most recent biopsy prior to primary treatment initiation
Details of the clinical stage (tumour, node, metastases) prior to primary treatment initiation
PSA levels prior to initiation of treatment
New definitions introduced Diagnostic PSA defined as occurring within 180 days prior to prostate cancer biopsy or 
transurethral resection of the prostate procedure
PSA, Prostate specific antigen.
provide the DCC with their data dictionaries to assess the 
extent to which they were comparable, complied with the 
ICHOM minimum dataset and could realistically comply 
by 2017. A project coordinator from the DCC collated 
the data dictionaries and, in addition to assessing compli-
ance with the ICHOM Localised Prostate Cancer Stan-
dardised dataset, identified data fields collected across 
participating sites but not in the ICHOM dataset. A final 
approved dataset and budget were deliverables from this 
work programme.
Data dictionaries were reviewed from 21/25 LDCs. 
Excluded data dictionaries were those from Italy (n=2), 
the Netherlands (n=1) and Spain (n=1) as these were not 
in English. For the four data dictionaries which were not 
documented in English, verbal contact was made with the 
principal investigator in each LDC, each of whom spoke 
English, to understand where gaps existed in their site’s 
ability to collect the ICHOM dataset. Results from the 
four LDCs where the data dictionary was not provided for 
analysis were not included in this analysis because verbal 
correspondence could not be validated. Figure 3 provides 
a summary of the results of the data dictionary exercise.
The Extended Prostate Cancer Index-26 questions15 
were collected by 43% of sites; 58% reported they 
could commence collection using this instrument in 
2017. Time points at which patient-reported outcome 
measure (PROM) data collection most often occurred 
were at baseline and at 12 months post treatment. Only 
one site complied with the follow-up schedule outlined 
by ICHOM.
There were a number of data fields collected by nomi-
nating sites which were not included in the ICHOM 
dataset. These included radiological diagnostic tests, 
prostate specific antigen (PSA) levels prior to treatment 
and annually; type of surgical approach undertaken for 
radical prostatectomy and biopsy details prior to active 
treatment (if this is not the same as the diagnostic biopsy).
A stakeholder meeting with principal investigators 
and senior information technology (IT) personnel from 
nominating sites was held in late 2015 prior to the devel-
opment of the project protocol. Its purpose was to share 
findings from the Data Discovery study, describe the 
proposed framework for data transfer and hosting, under-
stand potential barriers to data transfer, discuss potential 
ethical issues which might impact the project and identify 
broad barriers and enablers to project implementation.
The Executive Committee reviewed the results of the 
Data Discovery study. As a result of the heterogeneity of 
data collected across sites and difficulty reported by the 
principal investigators at the stakeholder meeting in being 
able to immediately incorporate the full ICHOM dataset, a 
two-tiered system for data was introduced. In general, data 
items were denoted as mandatory if they were likely to be 
required for risk adjustment or for generation of quality 
indicators. Start dates for each treatment were mandatory 
as they determined the time points for follow-up survey 
of patients. In addition, because a requirement of partic-
ipating in the project was that sites collected patient-re-
ported outcomes (and this received funding support 
by Movember), these fields were also mandatory. Tier 1 
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Figure 4 Description of the process by which (1) data 
from the Local Data Centres are transmitted to the TrueNTH 
Global Registry ; and (2) researchers will request and receive 
research data for statistical analysis. It will not be possible 
to removed data from the secure storage environment 
without authorisation designated by the Executive 
Committee. *Records of patients with invalid data will be 
rejected, with details shown in an Import Errors file. Valid 
patient records will be imported into the TrueNTH Global 
Registry 
items (T1) were considered mandatory and Tier 2 items 
(T2) were encouraged but were non-mandatory. This 
enabled sites to contribute with minimal upfront invest-
ment while allowing for sites collecting a more advanced 
dataset to contribute more extensive data. Figure 3 
outlines those data fields included as T1 and T2 fields. 
Table 1 summarises changes introduced by the Executive 
Committee following the Data Discovery review study. A 
survey will be distributed to LDCs and participating sites 
on an annual basis to understand structural factors which 
might impact on outcomes.
data management
A proposed data management strategy was presented 
to the stakeholder meeting and has been subsequently 
modified to facilitate data transfer from LDCs to the DCC 
and research activity within a secure environment. A data 
dictionary has been developed, with minor amendment 
to the ICHOM data dictionary. LDCs will be responsible 
for formatting data according to the data dictionary prior 
to transfer. Data will be transmitted through an Extract, 
Transfer, Load system in a normalised format. Records 
which do not comply with the required format or which 
violate the validation rules will be returned to sites for 
action. Data extracts will be transmitted to the DCC each 
6 months. It is probable that duplicate records will be 
transmitted, and that existing records may be updated 
if they comply with the field validation rules. A warning 
report will be provided to inform sites when data have 
been overwritten.
Data will be hosted in a secure environment with access 
restricted via a secure data access solution. Authorisation 
points will prevent data from being accessed without 
appropriate predetermined approvals. Once autho-
rised, users will have time-limited access to a Micro-
soft Windows-based remote desktop environment with 
controls on copy/paste, print and file transfer, and no 
external network access. The data itself are protected 
and cannot be extracted, placing tight controls over data 
exposure. Once research has been completed, it may be 
released through a subsequent authorisation process. 
Data import and handling procedures are summarised in 
figure 4. When discussed at the stakeholder meeting in 
December 2015, the group considered that this approach 
would provide adequate safeguard of data and satisfy 
requirement of human research ethics committees and 
information security review teams.
Future ProPosed ActIvIty
Quality indicators will be developed using a modified 
Delphi approach. This approach involves first identi-
fying from the literature potential quality indicators and 
then, though a series of rounds with selected experts, 
determining which ones rate highest for inclusion in 
the registry.16 Panel members will include a representa-
tive selection of men and their partners, specialty groups 
involved in the management of men with localised 
prostate cancer and researchers/epidemiologists with 
experience in data and prostate cancer disease. Project 
Steering Committee members will be invited to partici-
pate in this project.
Software has been developed to electronically capture 
PROMs (ePROMs). Patients may complete the ePROMs in 
the hospital or they may be forwarded via electronic mail 
for them to complete at home. An audit project will be 
undertaken to assess the quality of the data contributing 
to the TrueNTH Global Registry project. This activity will 
be led by LDCs and will be multifaceted. External vali-
dation with data sources such as administrative coding 
systems and cancer registries will assess the proportion 
of the eligible population that the local registry includes. 
Data dictionaries have been developed to provide clear 
rules on how data are defined and coded and have been 
distributed to all LDCs with the TrueNTH Global Registry 
protocol. Reliability of data will be assessed by LDCs 
through recapture of patient data on a small percentage 
of cases. Automated range and consistency validation 
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checks will be undertaken as data are imported into 
TrueNTH Global Registry to ensure that data outside 
permitted values are identified, rejected and returned to 
LDCs for review. Principal outcomes monitored by the 
registry are independently assessed by the patient and 
pathology/radiology reports, thereby minimising risk of 
outcome bias.
The PCC and DCC will collaborate to assess how 
to present indicators to participating sites and LDCs 
and to finalise the structural indicators to be collected 
periodically.
strengths And lImItAtIons
The TrueNTH Global Registryproject offers the potential 
to improve care provided to men with prostate cancer by 
using a consistent dataset to identify and reduce varia-
tion in patient outcomes. It is hypothesised that this will 
be achieved by assessing attributes of high-performing 
organisations and working with an engaged clinical team 
across countries to make local changes. The impact of 
these changes will be assessed by the registry in a consis-
tent and standardised approach through compliance 
with quality indicators. The project is ambitious and, if 
successful, may provide a transformational approach to 
quality and safety activity at a global scale.
The concept of a global registry is not unique. Interna-
tional registries have been established to monitor diseases 
and interventions associated with significant health 
burden such as orthopaedic surgery17 and transplanta-
tion18; others have been set up to monitor rare diseases, 
for which single-institution/single-country registries 
would take many years to accumulate enough meaningful 
data to advance disease treatment.19 Common priorities 
in the establishment phase of international registries 
include harmonising data through consistent data defi-
nitions. Other registries have used a similar approach to 
ICHOM in providing a framework so that common data 
elements can be shared between registries.20
The approach taken by the TurueNTH Global Registry 
to data analysis is to collect reversibly anonymised patient-
level data in a central data repository which has strict secu-
rity standards and controls over data access. A centralised 
approach provides an effective means of developing 
benchmark reports and undertaking consistent data vali-
dation checks on data, and a rich resource for initiating 
quality improvement research activities. Other registries 
have adopted a distributed approach to data analysis to 
avoid security issues, where each registry retains its own 
data and conducts analysis in a consistent manner.17 21 
Sites presenting the protocol to ethics committees for 
review have not found this to be a barrier provided appro-
priate security certificates are provided, but this will need 
to be monitored as more sites sign up to the registry.
There are a number of challenges which the TrueNTH 
Global Registryhas considered beyond its establishment 
phase. Experience from another international registry 
suggests that difficulty sustaining funding, inadequate 
local IT knowledge to provide uploads and changing data 
legislation across countries have potential to pose diffi-
culties.22 Maintaining sustained motivation and support 
of stakeholders is a challenge for all research activity. 
Movember has provided funds to assist sites in setting up 
automated data transfer solutions and more sustained 
funding to fund gaps in existing data collection. The 
DCC has developed user-friendly software to facilitate 
data uploads in file formats that are easily originated from 
existing registries. Legislative barriers have been mini-
mised by the transmission of reversibly anonymised data. 
Collection of PROMs is a core element of the registry yet, 
to date, has been poorly collected by participating sites 
and LDCs. It will provide a challenge to efficiently collect 
this information from patients, particularly at baseline due 
to the lag in coding and transmission of prostate cancer 
notification data by hospitals. However, high comple-
tion rates of 86% have been recorded by hospitals using 
ePROMs, attributed largely to them having an engaged 
and supported roll-out team.23 We will encourage sites 
to adopt such an approach and will monitor the impact 
of different strategies on PROMs completion rates in the 
immediate and longer terms. While funding has only been 
provided to collect PROMs at baseline and 12 months 
post-diagnosis/primary treatment, hospitals are encour-
aged to contribute additional PROMs if they are being 
collected and the software will not restrict the number 
of PROMs for each patient uploaded by hospitals. To 
maintain the motivation of sites, the PCC will distribute 
regular updates and the DCC will distribute six monthly 
quality indicator benchmark reports highlighting where 
participating sites sit relative to others. The Project 
Steering Committee will have regular web conferences to 
review data and discuss potential interventions to reduce 
variation. Recognition and academic credit will likely also 
encourage project participation and, to this end, author-
ship guidelines have been developed and agreed on and 
are documented in the study protocol. An advantage of 
this project is that sites already have established registries 
so additional burden to contribute to the international 
registry is minimal.
While other international registries have been devel-
oped, the novelty of this global clinical quality registry 
is its core purpose to provide useful, clinically relevant 
information back to contributing sites to enable global 
benchmarking and feedback which will empower local 
action. In doing so, we hope to realise the goal of reducing 
unwarranted variation and promoting excellence.
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